Evidence map›Paper›PMID 28028637›Full record

ArticleSurgery today2017

Phase I clinical trial of olprinone in liver surgery.

Hiroaki Fuji, Etsuro Hatano, Kohta Iguchi, Kenya Yamanaka, Tomoaki Yoh, Yoshinobu Ikeno, Satoru Seo, Kojiro Taura, Kentaro Yasuchika, Shiro Tanaka and 4 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Surgery today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Hiroaki FujiDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Etsuro HatanoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. shatano@hyo-med.ac.jp.
Kohta IguchiDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kenya YamanakaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tomoaki YohDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoshinobu IkenoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Satoru SeoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kojiro TauraDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kentaro YasuchikaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shiro TanakaDepartment of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
Hisanari IshiiDepartment of Anesthesia, Tenri Hospital, Tenri, Japan.
Mariko KobayashiDepartment of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Science, Niigata, Japan.
Kazuyuki UenoDepartment of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Science, Niigata, Japan.
Shinji UemotoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPNiigata University of Pharmacy and Applied Life Sciences · JPTenri Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePost-hepatectomy liver failure is one of the most serious complications liver surgeons must overcome. We previously examined olprinone, a selective phosphodiesterase III inhibitor, and demonstrated its hepatoprotective effects in rats and pigs. We herein report the results of a phase I clinical trial of olprinone in liver surgery (UMIN000004975).

methodsTwenty-three patients who underwent hepatectomy between 2011 and 2015 were prospectively registered. In the first 6 cases, olprinone (0.1 μg/kg/min) was administered for 24 h from the start of surgery. In the remaining 17 cases, olprinone (0.05 μg/kg/min) was administered from the start of surgery until just before the transection of the liver parenchyma. The primary endpoint was safety, and the secondary endpoint was efficacy. For the evaluation of efficacy, the incidence of post-hepatectomy liver failure in 20 hepatocellular carcinoma patients was externally compared with 20 propensity score-matched patients.

resultsNo intraoperative side effects were observed, and the morbidity rates in the analyzed cohorts were acceptable. The rate of post-hepatectomy liver failure frequency tended to be lower in the olprinone group.

conclusionsThe safety of olprinone in liver surgery was confirmed. The efficacy of olprinone will be re-evaluated in clinical trials.

Indexed as

HepatectomyAgedCarcinoma, HepatocellularCohort StudiesFemaleHumansImidazolesIncidenceLiver FailureLiver NeoplasmsMaleMiddle AgedPhosphodiesterase 3 InhibitorsPostoperative ComplicationsPropensity ScorePyridonesImidazolesolprinonePhosphodiesterase 3 InhibitorsPyridonesOlprinonePhase I clinical trialPost-hepatectomy liver failureSelective phosphodiesterase III inhibitorTranslational research

Identifiers

PMID28028637
OpenAlexW2563079849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.